PDF herunterladen
CC BY-NC-ND 4.0 · Asian J Neurosurg 2021; 16(01): 14-23
DOI: 10.4103/ajns.AJNS_186_20
Review Article

Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review

Arash Ghaffari-Rafi
1   John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, Hawaii
,
Shadeh Ghaffari-Rafi
2   Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa
,
Jose Leon-Rojas
3   Universidad Internacional del Ecuador, Escuela de Medicina, Quito
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Objective/Introduction: Although a critical chemotherapeutic, temozolomide's optimal regimen for 2016 World Health Organization (WHO) Grade II gliomas remains elusive, hence there is utility in not only cataloging survival outcomes of Grade II glioma subtypes against the background of temozolomide regimens, but also quantifying differences in progression-free survival (PFS) and overall survival (OS). Materials and Methods: A systematic review of MEDLINE, Embase, and Cochrane Central Register of Controlled Trails was conducted by using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis and the Cochrane Handbook of Systemic Reviews of Interventions. Results: Each molecular subtype of WHO Grade II glioma had a different temozolomide regimen identified as optimal in prolonging PFS and OS. For PFS, with temozolomide, the 25th, 50th, and 75th percentiles, were as follows (in months), respectively–A-wt II: 6.90, 12.95, and 19.95; A-mt II: 34.45, 36.01, and 39.60; OD II: 37.90, 46.00, and 55.03 (P = 0.016). For OS, the first quartile (25%), median (50%), third quartile (75%), were respectively identified (in months–A-wt II: 21.6 (median; n = 1); A-mt II: 60.6, 85.2, and 109.8; OD II: 86.1, 96.2, and 106.3 (P = 0.37). Conclusion: For each tumor molecular subtype, a different temozolomide regimen was identified as optimal for prolonging PFS and OS. Furthermore, regardless of temozolomide regimen, A-wt II had a significantly shorter PFS than A-mt II and OD-II. Overall, the data can provide useful prognostic insight to patients when making critical treatment decisions. Moreover, by cataloging and assessing survival outcomes per temozolomide regimen, such may facilitate future clinical trial design.

Key-words:

Astrocytoma - glioma - low-grade glioma - oligodendroglioma - overall survival - progression-free survival - temozolomide

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 29. April 2020

Angenommen: 27. September 2020

Artikel online veröffentlicht:
16. August 2022

© 2021. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-14.
  • 2 Grier J. Low-grade gliomas in adults. Oncologist 2006;11:681-93.
  • 3 Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry 2004;75:ii31-6.
  • 4 Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep 2010;10:224-31.
  • 5 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England. J Med 2005;352:987-96.
  • 6 Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: WHO/IARC; 2016.
  • 7 Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17:1521-32.
  • 8 Fu W, Wang W, Li H, Jiao Y, Weng J, Huo R, et al. High dimensional mass cytometry analysis reveals characteristics of the immunosuppressive microenvironment in diffuse astrocytomas. Front Oncol 2020;10:78.
  • 9 Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A, et al. The Cochrane Collaboration's Tool for Assessing Risk of Bias in randomised trials. BMJ 2011;343:d5928-928.
  • 10 Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
  • 11 Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015;349:7647.
  • 12 Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133-46.
  • 13 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
  • 14 Ghaffari-Rafi A, Samandouras G. Effect of treatment modalities on progression-free survival and overall survival in molecularly subtyped world health organization grade II diffuse gliomas: A systematic review. World Neurosurg 2020;133:366-8000.
  • 15 Buckner J, Giannini C, Eckel-Passow J, Lachance D, Parney I, Laack N, et al. Management of diffuse low-grade gliomas in adults-use of molecular diagnostics. Nat Rev Neurol 2017;13:340-51.
  • 16 Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 2017;28:1942-8.
  • 17 Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, et al. Chemotherapy for adult low-grade gliomas: Clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol 2017;19:242-51.
  • 18 Wijnenga MM, French PJ, Dubbink HJ, Dinjens WN, Atmodimedjo PN, Kros JM, et al. The impact of surgery in molecularly defined low-grade glioma: An integrated clinical, radiological, and molecular analysis. Neuro Oncol 2018;20:103-12.
  • 19 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Ver. 5.1.0. Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org. [Last accessed on 2020 Oct 12].
  • 20 Kruskal WH, Allen Wallis H. Use of ranks in one-criterion variance analysis. J Am Statistical Assoc 1952;47:260, 583-621.
  • 21 Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin 1945;1:80-3.
  • 22 Core Team R. A language and Environment for Statistical Computing. Foundation for Statistical Computing, Vienna, Austria; 2018. Available from: http://www.R-project.org/. [Last accessed on 2020 Oct 12].
  • 23 Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-6.
  • 24 Pellerino A, Franchino F, Pace A, Carapella C, Dealis C, Caroli M, et al. Temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: A phase II aino (Italian Association for Neuro-Oncology) study. Neuro-Oncol 2017;19 Suppl 3:iii21.
  • 25 Villani V, Merola R, Vidiri A, Fabi A, Carosi M, Giannarelli D, et al. Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: Activity, safety, and long-term follow-up. Tumori 2017;103:255-60.
  • 26 Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, et al. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. Eur J Cancer 2018;94:168-78.
  • 27 Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, et al. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. J Neurooncol 2017;135:273-84.
  • 28 Minichillo S, Franceschi E, Mura A, Tosoni A, Tallini G, Pession A, et al. The role of treatments in IDH mutant molecular astrocytomas. Ann Oncol 2017;28 Suppl 6:vi76.
  • 29 Li MY, Wang YY, Cai JQ, Zhang CB, Wang KY, Cheng W, et al. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. PLoS One 2015;10:e0130872.
  • 30 Metellus P, Coulibaly B, Colin C, De Paula AM, Vasiljevic A, Taieb D, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719-29.
  • 31 Straube C, Kessel KA, Schmidt-Graf F, Krieg SM, Meyer B, Gempt J, et al. A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 Results from a multi-center survey. BMC Cancer 2018;18:907.
  • 32 van den Bent MJ. Oligodendrogliomas: A short history of clinical developments. CNS Oncol 2015;4:281-5.
  • 33 Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 2007;82:281-8.
  • 34 Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. J Neurooncol 2017;135:535-43.